NEW YORK – On the heels of a $25 million financing round, Australian diagnostic instrument and test developer Genetic Signatures is expanding its European and US marketing and sales operations and preparing an application to the US Food and Drug Administration for clearance of a syndromic enteric protozoa kit.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.